We advise businesses across a variety of sectors on regulatory, permitting and compliance related issues.
Particular areas of strength include air and water pollution, waste management and shipment, land contamination, noise abatement and hazardous substances.
The global slowdown has led to significant corporate restructuring, plant closures and mothballing. Environmental issues are often a key consideration in these decisions given the need to minimise the environmental legacy and eliminate longer term risks.
We advise on health and safety issues in transactions and on a stand-alone basis. This ranges from strategic issues concerning board-level health and safety responsibilities to practical guidance over health and safety issues, relationships with contractors and health and safety-related proceedings.
We also assist on measures to prevent bribery and corruption issues connected to environmental and wider compliance matters.
News & insights
News: 03 FEBRUARY 2020
A&O’s global Projects, Energy, Natural Resources and Infrastructure group has finished top of the IJGlobal and Dealogic league tables, making 2019 another highly successful year.Read more
Publications: 27 JUNE 2019
Yesterday, the French specialised committee on cannabis (CSST), which was established in mid-2018, held its last meeting and presented its final recommendations for the implementation of a medical cannabis pilot programme to the French National Agency for Medicines and Health Products Safety (ANSM).Read more
Publications: 12 JUNE 2019
Following the penultimate meeting of the specialised committee on cannabis (CSST) established by the French National Agency of Medicine and Health Products Safety (ANSM) (see our previous blog posts "French ANSM temporary scientific committee pursues activities on modalities of medical cannabis availability" and "French ANSM recommends medical use of cannabis under certain conditions"), the French Senate held a hearing on 28 May 2019 entitled "Cannabis, a major public health issue" during which the senators present at the hearing came (despite existing concerns) to a quasi-consensus regarding the need of legally permitting medical cannabis in France. In the days and weeks following the debate, both politicians and experts, amongst others Nicolas AUTHIER, the chairman of the CSST, provided some further insights on the future of medical cannabis in France.Read more
Allen & Overy are market leaders.
Chambers Europe 2016 (Regulatory and Public Affairs)